Deep Value, Special Situations, Biotech
Seeking Alpha Analyst Since 2008
Strength in Ziopharm continues to puzzle me. Perhaps a halo effect from Intrexon's S-1 filing? I remain hopeful that Pali ends up creating value. Looking for readout in brain cancer later this Fall.
Disclosure: I am long ZIOP.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.